KLOTHO PROTEIN, FIBROBLAST GROWTH FACTOR AND SCLEROSTIN IN CHRONIC HEART FAILURE
Abstract
Chronic heart failure (CHF) is a global medical, social and economic problem. CHF is a syndrome caused by an imbalance in the neurohumoral regulation of the cardiovascular system, which is accompanied by a violation of the systolic and/or diastolic function of the heart. Currently, the search for and study of new biological markers that can ensure early diagnosis of CHF, serve as a laboratory tool for assessing the effectiveness of treatment, or be used as prognostic markers and risk stratification criteria continues.
References
Riccardi M., Sammartino A., Piepoli M., et al. Heart failure: an update from the last years and a look at the near future // ESC Heart Fail. 2022. Vol. 9, N 6. P. 3667–3693. doi: 10.1002/ehf2.14257. Erratum in: ESC Heart Fail. 2023. Vol. 10, N 3. P. 2143.
Golukhova E.Z., Alieva A.M. Clinical significance of determining natriuretic peptides in patients with chronic heart failure // Cardiology and cardiovascular surgery. 2007. No. 1. P. 45–51. EDN: HGTYXS
Bozkurt B., Coats A., Tsutsui H., et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure // J Card Fail. 2021. S1071-9164(21)00050-6. doi: 10.1016/j.cardfail.2021.01.022. Epub ahead of print.
Szlagor M., Dybiec J., Młynarska E., et al. Chronic Kidney Disease as a Comorbidity in Heart Failure // Int J Mol Sci. 2023. Vol. 24, N 3. P. 2988. doi: 10.3390/ijms24032988
